Evidence map›Paper›PMID 31386233›Full record

ReviewGlia2020

The role of microglia in ischemic preconditioning.

Ashley McDonough, Jonathan R Weinstein

Open access · greenAbstract readReview
In one paragraph

Review in Glia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Neuroimmune Mechanisms and Emerging Intervention Strategies for Post-Stroke Fatigue: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Role of microglia after subarachnoid hemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Ischemic Tolerance Induced by Glial Cells.Neurochemical research · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Regulatory T cells in ischemic stroke.Acta pharmacologica Sinica · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ashley McDonoughDepartment of Neurology, School of Medicine, University of Washington, Seattle, Washington.ORCID 0000-0003-3864-9449
Jonathan R WeinsteinDepartment of Neurology, School of Medicine, University of Washington, Seattle, Washington.ORCID 0000-0001-6080-9758
University of Washington · US

Funding

Microglial Interferon Signaling and Ischemic PreconditioningR01NS076620 · NINDS · UNIVERSITY OF WASHINGTON · PI WEINSTEIN, JONATHAN R · 2011 to 2015
$1.7M
Microglial Toll-like Receptor-4 and Ischemic PreconditioningK02NS065008 · NINDS · UNIVERSITY OF WASHINGTON · PI WEINSTEIN, JONATHAN R · 2009 to 2013
$838k
Interferon Signaling in Microglia Mediates Neuroprotection in StrokeF32NS100245 · NINDS · UNIVERSITY OF WASHINGTON · PI MCDONOUGH, ASHLEY · 2017 to 2019
$198k
NINDS NIH HHS F32 NS100245NINDS NIH HHS K02 NS065008NINDS NIH HHS NS065008NINDS NIH HHS NS076620NINDS NIH HHS NS100245NINDS NIH HHS R01 NS076620
6 · The paper itself

Abstract

Ischemic preconditioning (IPC) is an experimental phenomenon in which a brief ischemic stimulus confers protection against a subsequent prolonged ischemic event. Initially thought to be due to mechanistic changes in neurons, our understanding of IPC has evolved to encompass a global reprogramming of the Central Nervous System (CNS) after transient ischemia/reperfusion that requires innate immune signaling pathways including Toll-like receptors (TLRs) and Type I interferons. Microglia are the CNS resident neuroimmune cells that express these key innate immune receptors. Studies suggest that microglia are required for IPC-mediated neuronal and axonal protection. Multiple paradigms targeting TLRs have converged on a distinctive Type I interferon response in microglia that is critical for preconditioning-mediated protection against ischemia. These pathways can be targeted through administration of TLR agonists, cytokines including interferon-β, and pharmaceutical agents that induce preconditioning through cross-tolerance mechanisms. Transcriptomic analyses and single cell RNA studies point to specific gene expression signatures in microglia that functionally shift these mutable cells to an immunomodulatory or protective phenotype. Although there are technological challenges and gaps in knowledge to overcome, the targeting of specific molecular signaling pathways in microglia is a promising direction for development of novel and effective pharmacotherapies for stroke. Studies on preconditioning in animal models, including nonhuman primates, show promise as prophylactic preconditioning treatments for selected at risk patient populations. In addition, our growing understanding of the mechanisms of IPC-mediated protection is identifying novel cellular and molecular targets for therapeutic interventions that could apply broadly to both acute stroke and chronic vascular cognitive impairment patients.

Indexed as

Ischemic PreconditioningAnimalsBrain IschemiaCytokinesHumansMicrogliaStrokeToll-Like ReceptorsCytokinesToll-Like ReceptorsinterferonsischemiamicrogliapreconditioningTLRs

Identifiers

PMID31386233
PMCPMC9035311
OpenAlexW2964777348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.